MX2009001070A - Uso de proteina con actividad inhibidora de melanoma (mia) como un indicador temprano para la respuesta terapeutica en melanoma. - Google Patents

Uso de proteina con actividad inhibidora de melanoma (mia) como un indicador temprano para la respuesta terapeutica en melanoma.

Info

Publication number
MX2009001070A
MX2009001070A MX2009001070A MX2009001070A MX2009001070A MX 2009001070 A MX2009001070 A MX 2009001070A MX 2009001070 A MX2009001070 A MX 2009001070A MX 2009001070 A MX2009001070 A MX 2009001070A MX 2009001070 A MX2009001070 A MX 2009001070A
Authority
MX
Mexico
Prior art keywords
melanoma
mia
concentration
biological sample
protein
Prior art date
Application number
MX2009001070A
Other languages
English (en)
Inventor
Carla Heise
Nguyen Tan
Eleni Venetsanakos
Michel Faure
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2009001070A publication Critical patent/MX2009001070A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4704—Inhibitors; Supressors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención proporciona un método para determinar una respuesta de un sujeto mamífero que tiene células de tumor de melanoma al tratamiento con un agente inhibidor de melanoma. En un aspecto, el método comprende (a) determinar una primera concentración de la Proteína con Actividad Inhibidora de Melanoma (MIA) en una primera muestra biológica tomada del sujeto mamífero antes del tratamiento con el agente inhibidor de melanoma; (b) determinar una segunda concentración de MIA en una segunda muestra biológica del sujeto mamífero tomada después del tratamiento con el agente inhibidor de melanoma, y (c) comparar la primera y la segunda concentraciones de MIA, en donde una disminución en la segunda concentración de MIA medida en la segunda muestra biológica en comparación con la primera concentración de MIA medida en la primera muestra biológica indica una respuesta positiva al tratamiento con el agente inhibidor de melanoma.
MX2009001070A 2006-07-28 2007-07-26 Uso de proteina con actividad inhibidora de melanoma (mia) como un indicador temprano para la respuesta terapeutica en melanoma. MX2009001070A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82075606P 2006-07-28 2006-07-28
PCT/US2007/016848 WO2008013912A1 (en) 2006-07-28 2007-07-26 Use of melanoma inhibitory activity (mia) protein as an early indicator for therapeutic response in melanoma

Publications (1)

Publication Number Publication Date
MX2009001070A true MX2009001070A (es) 2009-04-23

Family

ID=38626977

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009001070A MX2009001070A (es) 2006-07-28 2007-07-26 Uso de proteina con actividad inhibidora de melanoma (mia) como un indicador temprano para la respuesta terapeutica en melanoma.

Country Status (11)

Country Link
US (2) US8288087B2 (es)
EP (1) EP2049904A1 (es)
JP (2) JP5274458B2 (es)
KR (1) KR20090046893A (es)
CN (1) CN101512343A (es)
AU (1) AU2007277144B2 (es)
BR (1) BRPI0715062A2 (es)
CA (1) CA2659270A1 (es)
MX (1) MX2009001070A (es)
RU (1) RU2480769C2 (es)
WO (1) WO2008013912A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2608171C (en) 2005-05-13 2014-02-04 Novartis Ag Use of quinolinone compounds for treating drug resistant cancers
CA2679268A1 (en) * 2007-03-09 2008-09-18 Novartis Ag Treatment of melanoma
JP5568807B2 (ja) * 2008-06-06 2014-08-13 静岡県 プロテオミクス解析を用いたメラノーママーカーの同定
WO2011044072A1 (en) * 2009-10-05 2011-04-14 Novartis Ag Combination of raf-265 and an activator of ampk for use in the treatment of a proliferative disease
DE102015103158A1 (de) 2014-03-04 2015-09-10 Bergische Universität Wuppertal Verbindungen für die Behandlung des Melanoms
US20170184602A1 (en) * 2014-04-24 2017-06-29 Pfizer Inc. Cancer treatment
KR20180091024A (ko) * 2015-12-02 2018-08-14 클리어라이트 다이어그노스틱스 엘엘씨 암의 검출 및 모니터링을 위해 종양 조직 시료를 준비하고 분석하는 방법
ES3015712T3 (en) * 2019-11-04 2025-05-07 Ummon Healthtech Method of, and computerized system for labeling an image of cells of a patient

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4725538A (en) * 1985-10-25 1988-02-16 The Beth Israel Hospital Association Method of assaying the presence of cancer cells
WO1991006866A2 (en) * 1989-11-03 1991-05-16 Morton Donald L Urinary tumor associated antigen, antigenic subunits uses and methods of detection
WO1995003328A2 (de) * 1993-07-20 1995-02-02 Boehringer Mannheim Gmbh Melanom-inhibierendes protein
US5869332A (en) * 1994-06-03 1999-02-09 Southwest Foundation For Biomedical Research Metastatic melanoma cell lines from monodelphis domestica for use in anti-cancer agent discovery
EP1682512B1 (en) * 2003-11-04 2010-03-31 Bayer Pharmaceuticals Corporation IMMUNOHISTOCHEMICAL METHODS FOR MONITORING pERK LEVELS
RU2280483C2 (ru) * 2004-07-05 2006-07-27 Ростовский научно-исследовательский онкологический институт МЗ РФ Способ определения эффективности противоопухолевого лечения меланом кожи
WO2007009191A1 (en) * 2005-07-21 2007-01-25 Newsouth Innovations Pty Limited Method for treating cancer

Also Published As

Publication number Publication date
AU2007277144B2 (en) 2012-01-19
JP5274458B2 (ja) 2013-08-28
RU2009106718A (ru) 2010-09-10
US20100009392A1 (en) 2010-01-14
KR20090046893A (ko) 2009-05-11
BRPI0715062A2 (pt) 2013-06-04
JP2013083665A (ja) 2013-05-09
JP2009544970A (ja) 2009-12-17
CN101512343A (zh) 2009-08-19
AU2007277144A1 (en) 2008-01-31
US8288087B2 (en) 2012-10-16
RU2480769C2 (ru) 2013-04-27
WO2008013912A1 (en) 2008-01-31
CA2659270A1 (en) 2008-01-31
EP2049904A1 (en) 2009-04-22
US20130237546A1 (en) 2013-09-12

Similar Documents

Publication Publication Date Title
MX2009001070A (es) Uso de proteina con actividad inhibidora de melanoma (mia) como un indicador temprano para la respuesta terapeutica en melanoma.
CA2815892C (en) Analytical methods and arrays for use in the same
EP4647505A3 (en) Biomolecular probes and methods of detecting gene and protein expression
EP4306955A3 (en) Integrated functional and molecular profiling of cells
BRPI0510617A (pt) uso de expressão de il-17 para prever inflamação de pele; processos de tratamento
BRPI0915619A2 (pt) métodos para determinar uma probabilidade de que um sujeito tenha contribuído com material genético para amostra de teste de material genético, para caracterizar amostra de teste de material genético e para determinar se uma pessoa de interesse contribuiu com material genético para uma amostra de teste de material genético, kit para análise de amostra de teste de material genético e sistema para determinar se um sujeito contribuiu com material genético para uma amostra
TW200617380A (en) Concentration determination in a diffusion barrier layer
BRPI1013688A8 (pt) Proteínas de ligação de il-17.
BR112012031071A2 (pt) 8-proteínas de ligação à il-1
BR112015023120A2 (pt) método para identificar um indivíduo com uma doença ou disfunção, método para prever a responsividade de um indivíduo com uma doença ou disfunção, método para determinar a probabilidade de que um indivíduo com uma doença ou disfunção exibirá benefício do tratamento, método para selecionar uma terapia, usos de um antagonista de ligação do eixo pd-l1, ensaio para identificar um indivíduo com uma doença, kit de diagnóstico, método para avaliar uma resposta ao tratamento e método para monitorar a resposta de um indivíduo tratado
EA201391627A1 (ru) Анализ на наличие лизилоксидазоподобных белков 2 и способы его применения
WO2014170497A3 (en) Method for identifying the quantitative cellular composition in a biological sample
ATE554389T1 (de) Apex als marker für lungenkrebs
NZ607282A (en) Method for using gene expression to determine prognosis of prostate cancer
BR112013010952A2 (pt) sistemas de rmn e métodos para a detecção rápida de analisados
CO6680668A2 (es) Ensayos biomarcadores para detectar o medir inhibición de actividad quinasa tor
MY198081A (en) Urinalysis device and dry reagent for quantitative urinalysis
EA201590630A1 (ru) Способы лечения и диагностики, связанные с лизилоксидазоподобным белком 2 (loxl2)
MX360236B (es) Uso de marcadores en el diagnostico y tratamiento de cancer de prostata.
EP2569635A4 (en) METHOD FOR DIAGNOSIS AND / OR TREATMENT OF ENZEPHALITIS OR EPILEPSY
MXPA05006382A (es) Uso de nicotinamida n-metiltransferasa como un marcador para cancer colorrectal.
AR071034A1 (es) Uso de la catepsina c en el diagnostico de susceptibilidad al dolor y para el tratamiento del dolor
ATE443775T1 (de) Hif-prolylhydroxylase-aktivitätstest
ATE468535T1 (de) Verwendung von nnmt als marker für lungenkrebs
PE20120592A1 (es) Metodo con biomarcadores para el seguimiento de un tratamiento

Legal Events

Date Code Title Description
FG Grant or registration